As the response rate (RR) to anti-EGFR MoAbs remains as low as 10–20 % in patients with metastatic colorectal cancer (mCRC) [2], several studies have been performed to identify markers predicting the efficacy of these agents. Here, EGFR is linked to metastatic colorectal cancer.